TIME EVENT SPEAKER
Moderators: D. Iancu M. Kelly J. Ospel and S. Peschillo
07:30 - 08:00 Welcome Coffee / Tea
08:00 - 08:20 Pictorial review of cSDH & meningioma angioarchitecture: implications for embolization R. Kumar (Pending Confirmation)
08:24 - 08:44 Evidence of prospective trials on MMAE for cSDH: opportunities and challenges - will stand-alone MMAE become standard of care? JJ. Shankar
08:48 - 09:08 cSDH MMAE: Is one agent superior to others? Can we combine MMAE and SDH drainage into one procedure in the angiosuite? P. Lylyk
09:12 - 09:32 New generation of magnetically steerable robotic “nanocatheters” and arcuable microwires P. Mosimann
09:35 - 10:05 Coffee Break & Industry Booth Visits
Next Moderators: A. Siddiqui,B. Van Adel, R. Fahed and P. Muthusami
10:05 - 10:25 3D-printed and placenta models: defining the metrics to capture intuition-based practices and improve lifelong learning and teaching of INR techniques (including liquid embolics) S. Peschillo
10:30 - 12:00 Recorded friendly competition on AVM model panel discussions and voting
12:00 - 13:00 Lunch
Next Moderators: B. van Adel, D.Tampieri, J. Raymond, F. Arnberg and I. Radovanovic
13:00 - 14:00 KEYNOTE LECTURE: How brain and spine AVMs form, mature and involute - underlying molecular and pharmacological targets G. Rodesch & I. Radovanovic
14:05 - 14:25 What is an AVM “nidus”? Concept of venous segmentation and therapeutic considerations R. Chapot
14:28 - 14:40 Ahead of the curve: the art and science of wire and microcatheter “shapeology” to increase the chances of successful arterial and venous navigation R. Chapot
14:43 - 14:55 Next generation game changer embolic agent for endovascular cure of AVMs and hypervascular tumors A. Gil
14:58 - 15:18 DSA and MR fusion: the key to single session combined TAE/TVE embocure? How easy is it to implement ? F. Arnberg
15:20 - 15:55 Coffee Break & Industry Booth Visits
Next Moderators: A. Siddiqui, F. Arnberg, J. Shankar and R. Chapot
15:58 - 16:10 Pragmatic care trials on AVMs: natural history and treatment benefit:harm ratio (TOBAS) D. Roy
16:13 - 16:25 Most AVMs are surgical: which ones benefit from embolization / hybrid approach? I. Radovanovic
16:28 - 16:40 Should we even treat AVMs ? Most/least benefit from SRS alone vs combined SRS-embolization? B. Karlsson
16:43 - 16:55 Modern techniques and innovations for fetal and pediatric AV shunts P. Muthusami
17:00 - 18:00 6’ talks on Devices & Innovations